Evolution of Immunotherapy and Maintenance Therapy for Advanced Urothelial Carcinoma

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Phase I/II EV-103 cohort K: enfortumab vedotin with or without pembrolizumab as first-line treatment in cisplatin-ineligible locally advanced urothelial cancer, presented at ESMO and reported by Clinical Care Options (CCO)

CheckMate 274: pretreatment tumor and immune features and DFS with adjuvant nivolumab in high-risk muscle-invasive UC following radical resection, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Experts highlight key studies being reported at the upcoming 2022 ESMO Congress in this commentary from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Released: September 8, 2022